CLINICAL TRIALS PROFILE FOR AVENTYL HYDROCHLORIDE

All Clinical Trials for AVENTYL HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01944657 ↗	Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study	Withdrawn	Central Michigan University	N/A	2013-09-01	A. Introduction to the Problem This field experiment is intended to explore whether supplemental transcranial magnetic stimulation (TMS) is more effective than standard medication mono-therapy for the treatment of major depressive disorder. Transcranial magnetic stimulation (TMS) is now included in the practice guidelines of the American Psychiatric Association for the treatment of major depression. B. Importance of the Area of Study The safety, efficacy and value of TMS treatment has been established through the four-phase FDA approval process. The evidence of TMS safety and efficacy derives from multiple, peer reviewed, double-blind, randomized, control trials (RCT) with sham control as well as strict enrollment and methodological requirements. TMS is now used in actual clinical practice and there is an opportunity to extend laboratory research and typical, highly controlled field settings to applied settings. This study is designed to gather data on safety, efficacy and utility of TMS as it is used in clinical practice. C. Need for Additional Research Efficacy and safety of these interventions have been scientifically established and meta-analyses of these studies underscore the efficacy and safety of two treatment interventions to be employed in this study: 1) standard medication monotherapy and 2) standard medication therapy supplemented with TMS. However, many authors conclude that depression can be difficult to treat and there is an ongoing need for additional research. Depression remains a major public health problem.
NCT01944657 ↗	Supplemental Transcranial Magnetic Stimulation (TMS) vs. Standard Medication Monotherapy for Treating Major Depression: An Exploratory Field Study	Withdrawn	Sheppard Pratt Health System	N/A	2013-09-01	A. Introduction to the Problem This field experiment is intended to explore whether supplemental transcranial magnetic stimulation (TMS) is more effective than standard medication mono-therapy for the treatment of major depressive disorder. Transcranial magnetic stimulation (TMS) is now included in the practice guidelines of the American Psychiatric Association for the treatment of major depression. B. Importance of the Area of Study The safety, efficacy and value of TMS treatment has been established through the four-phase FDA approval process. The evidence of TMS safety and efficacy derives from multiple, peer reviewed, double-blind, randomized, control trials (RCT) with sham control as well as strict enrollment and methodological requirements. TMS is now used in actual clinical practice and there is an opportunity to extend laboratory research and typical, highly controlled field settings to applied settings. This study is designed to gather data on safety, efficacy and utility of TMS as it is used in clinical practice. C. Need for Additional Research Efficacy and safety of these interventions have been scientifically established and meta-analyses of these studies underscore the efficacy and safety of two treatment interventions to be employed in this study: 1) standard medication monotherapy and 2) standard medication therapy supplemented with TMS. However, many authors conclude that depression can be difficult to treat and there is an ongoing need for additional research. Depression remains a major public health problem.

Clinical Trial Conditions for AVENTYL HYDROCHLORIDE

Condition Name

Condition Name for AVENTYL HYDROCHLORIDE
Intervention	Trials
1. Major Depressive Disorder	1
1. Major Depressive Disorder.	1

Condition MeSH

Condition MeSH for AVENTYL HYDROCHLORIDE
Intervention	Trials
Depression	1
Depressive Disorder, Major	1
Depressive Disorder	1

Clinical Trial Locations for AVENTYL HYDROCHLORIDE

Trials by Country

Trials by Country for AVENTYL HYDROCHLORIDE
Location	Trials
United States	1

Trials by US State

Trials by US State for AVENTYL HYDROCHLORIDE
Location	Trials
Maryland	1

Clinical Trial Progress for AVENTYL HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for AVENTYL HYDROCHLORIDE
Clinical Trial Phase	Trials
N/A	1

Clinical Trial Status

Clinical Trial Status for AVENTYL HYDROCHLORIDE
Clinical Trial Phase	Trials
Withdrawn	1

Clinical Trial Sponsors for AVENTYL HYDROCHLORIDE

Sponsor Name

Sponsor Name for AVENTYL HYDROCHLORIDE
Sponsor	Trials
Central Michigan University	1
Sheppard Pratt Health System	1

Sponsor Type

Sponsor Type for AVENTYL HYDROCHLORIDE
Sponsor	Trials
Other	2

AVENTYL HYDROCHLORIDE Market Analysis and Financial Projection

Last updated: May 5, 2026

AVENTYL HYDROCHLORIDE: Clinical Trial Update, Market Analysis, and Projections

What is “Aventyl hydrochloride” in today’s drug market?

“Aventyl hydrochloride” is the brand name for amitriptyline hydrochloride. Amitriptyline is a first-generation tricyclic antidepressant (TCA) marketed as a generic in most developed markets.

Because amitriptyline is off-patent in major jurisdictions, this market profile is shaped more by generic supply, payer preferences, and safety/tolerability trade-offs than by ongoing proprietary clinical development.

---

Clinical trials update: Is there active development tied to “Aventyl hydrochloride”?

No proprietary clinical-trial pipeline anchored to the brand name “Aventyl hydrochloride” is evident in public registries at the level needed for a branded clinical-trials update. Public trial activity for amitriptyline exists in broad therapeutic contexts, but it is typically investigator-led, historical, comparative, or repurposing-focused rather than brand-owned registrational development.

What does the public clinical landscape show for amitriptyline?

Publicly available trial records for amitriptyline tend to fall into these buckets:

• Depression and antidepressant comparisons (older and comparative designs; limited relevance to current branded registrational endpoints)
• Pain syndromes (neuropathic pain, chronic pain, headache prophylaxis studies; often using low-dose amitriptyline)
• Sleep and behavioral symptom studies (smaller investigator-led trials)
• Switching and tolerability comparisons (generic-to-generic equivalence style studies are not the same as branded “new development”)

Actionability for investors and R&D planners: for a drug like amitriptyline, the key “clinical” events are less about new labeling and more about real-world formulary uptake, managed-care step-therapy behavior, and safety monitoring trends.

---

Market analysis: How does amitriptyline (Aventyl) perform commercially?

Market positioning

Amitriptyline sits in a mature, low-cost antidepressant segment where:

• Generic pricing dominates
• Payer-driven step therapy limits branded differentiation
• Clinician prescribing depends on tolerability, comorbidities, and target condition

Demand drivers

• Chronic neuropathic pain and chronic pain pathways use low-dose amitriptyline
• Depression remains a baseline TCA option in some settings, but modern practice often favors SSRIs/SNRIs unless cost or specific symptom patterns drive TCA selection
• Off-label use continues to support volume, especially where guidelines include TCA options for neuropathic pain

Demand constraints

• Anticholinergic burden (dry mouth, constipation, blurred vision)
• Cardiovascular safety concerns in at-risk populations (QT prolongation risk in susceptible patients)
• Sedation and weight gain affecting discontinuation in real-world use
• Geriatric prescribing caution under anticholinergic and sedation risk frameworks

---

Pricing and access: what matters for projection?

Generic competition effects

In most major markets, amitriptyline is available as multiple generics. That typically yields:

• Low net prices relative to branded antidepressants
• Stable but limited upside from new “clinical evidence,” unless it changes guideline behavior or payer rules

Formulary dynamics

Payers generally manage TCAs through:

• Preferred generics lists
• Step therapy for depression indications
• Condition-based pathways for pain and headache prophylaxis

This means volume growth is most sensitive to guideline adherence and switching patterns, not new monotherapy differentiation.

---

Projection: What is the likely forward trajectory for “Aventyl hydrochloride” (amitriptyline)?

Base-case projection

For a mature, off-patent molecule with broad generic access, the most realistic commercial model is:

• Stable to modest volume growth driven by pain management uptake and continued off-label prescribing
• Flat to slightly declining unit revenue due to generic price pressure
• Limited labeling-driven step-change unless an evidence package triggers payer or guideline shifts

Three-scenario model (market value impact)

All scenarios reflect mature generic dynamics; differences are driven by guideline and payer behavior rather than brand-specific clinical development.

Scenario	Volume trend	Net pricing trend	Net market value trend
Conservative	Flat	Down slightly	Flat to down
Base case	Low single-digit growth	Flat to down	Low single-digit growth to flat
Upside	Moderate growth	Flat	Low to mid single-digit growth

Forecast horizon: 3 to 5 years is typically the useful window for mature generics where major changes come from formulary policy shifts.

---

Strategic implications for R&D and investment

Where value can still be created

For amitriptyline, “value creation” is usually not about developing amitriptyline itself, but about:

• Novel formulations that reduce side effects (e.g., improved tolerability profiles)
• Target-specific dosing strategies supported by pragmatic clinical evidence
• Combination approaches if they can change payer outcomes (only if defensible data supports meaningful endpoints)

What to avoid

• Expecting brand-level market share gains from minor incremental studies
• Overestimating the commercial impact of non-registrational trials

---

Key Takeaways

• “Aventyl hydrochloride” is amitriptyline hydrochloride, a mature generic TCA with limited prospects for branded label expansion.
• Public clinical trial activity exists for amitriptyline, but it does not show a clear, brand-owned registrational pipeline that would support a branded clinical update.
• Market outlook is driven by generic competition and payer/formulary behavior, not proprietary innovation.
• Projections point to stability with modest volume growth and price pressure, yielding flat-to-low growth market value under most scenarios.

---

FAQs

1. Is Aventyl hydrochloride still protected by patents in major markets?

Aventyl hydrochloride corresponds to amitriptyline hydrochloride, which is widely generic. Patent protection for the original molecule is not the dominant market force.

2. What clinical areas most often use amitriptyline today?

Amitriptyline is commonly used for depression and widely used in practice for neuropathic pain and other chronic pain conditions.

3. Do new clinical trials usually change amitriptyline’s market?

Trial results can affect guideline and payer preferences, but market impact is typically modest for off-patent generics unless practice-changing endpoints lead to formulary changes.

4. What risks most affect prescribing trends?

Anticholinergic effects, sedation, and cardiovascular risk in susceptible patients drive caution and discontinuation patterns.

5. Where could future growth come from?

Growth is most plausible from improved tolerability strategies (formulation or dosing), expanded guideline endorsements for specific pain states, and payer pathway changes that keep TCAs in earlier lines for defined conditions.

---

References

[1] National Library of Medicine (NLM). Amitriptyline. PubChem Compound Summary. https://pubchem.ncbi.nlm.nih.gov/
[2] U.S. Food and Drug Administration. Drug Labels (amitriptyline hydrochloride; representative labeling entries). https://www.accessdata.fda.gov/
[3] World Health Organization (WHO). ATC classification: N06AA (Tricyclic antidepressants). https://www.whocc.no/atc/
[4] National Institute for Health and Care Excellence (NICE). Depression and neuropathic pain guidance (recommendations including TCA options). https://www.nice.org.uk/
[5] ClinicalTrials.gov. Amitriptyline clinical trials search results. https://clinicaltrials.gov/